Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016, Article ID 7891374, 9 pages
http://dx.doi.org/10.1155/2016/7891374
Research Article

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance

1Division of Gastroenterology, Department of Internal Medicine, Dongtan Sacred Heart Hospital, Hallym University School of Medicine, Gyeonggi-do 18450, Republic of Korea
2Division of Gastroenterology, Department of Internal Medicine, Hangang Sacred Heart Hospital, Hallym University School of Medicine, Seoul, Republic of Korea

Received 14 October 2015; Revised 30 December 2015; Accepted 11 January 2016

Academic Editor: Haruhiko Sugimura

Copyright © 2016 Hyun Joo Jang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics, 2009,” CA: A Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Shin, K.-Z. Kim, K.-W. Jung et al., “Increasing trend of colorectal cancer incidence in Korea, 1999–2009,” Cancer Research and Treatment, vol. 44, no. 4, pp. 219–226, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. S. H. Park, C. W. Song, Y. B. Kim et al., “Clinicopathological characteristics of colon cancer diagnosed at primary health care institutions,” Intestinal Research, vol. 12, no. 2, pp. 131–138, 2014. View at Google Scholar
  5. J. B. O'Connell, M. A. Maggard, and C. Y. Ko, “Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging,” Journal of the National Cancer Institute, vol. 96, no. 19, pp. 1420–1425, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Boghossian and A. Hawash, “Chemoprevention in colorectal cancer—where we stand and what we have learned from twenty year's experience,” Surgeon, vol. 10, no. 1, pp. 43–52, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Zhang, Y. Yin, S.-J. Xu, and W.-S. Chen, “5-Fluorouracil: mechanisms of resistance and reversal strategies,” Molecules, vol. 13, no. 8, pp. 1551–1569, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. L. Rothenberg, “Topoisomerase I inhibitors: review and update,” Annals of Oncology, vol. 8, no. 9, pp. 837–855, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. J. F. Pizzolato and L. B. Saltz, “The camptothecins,” Lancet, vol. 361, no. 9376, pp. 2235–2242, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Fuchs, E. P. Mitchell, and P. M. Hoff, “Irinotecan in the treatment of colorectal cancer,” Cancer Treatment Reviews, vol. 32, no. 7, pp. 491–503, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. D. A. Litvak, A. J. Bilchik, and M. C. Cabot, “Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: a novel treatment strategy,” Journal of Gastrointestinal Surgery, vol. 7, no. 1, pp. 140–148, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Van Cutsem and G. H. Blijham, “Irinotecan versus infusional 5- fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group,” Seminars in Oncology, vol. 26, no. 1, supplement 5, pp. 13–20, 1999. View at Google Scholar
  13. Y. Liu, W. Tang, J. Wang et al., “Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies,” Cancer Causes and Control, vol. 25, no. 2, pp. 237–249, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. J. N. Poynter, S. B. Gruber, P. D. R. Higgins et al., “Statins and the risk of colorectal cancer,” The New England Journal of Medicine, vol. 352, no. 21, pp. 2184–2192, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Bardou, A. Barkun, and M. Martel, “Effect of statin therapy on colorectal cancer,” Gut, vol. 59, no. 11, pp. 1572–1585, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Blais, A. Desgagné, and J. LeLorier, “3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the risk of cancer: a nested case-control study,” Archives of Internal Medicine, vol. 160, no. 15, pp. 2363–2368, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. M. R. Graaf, A. B. Beiderbeck, A. C. G. Egberts, D. J. Richel, and H.-J. Guchelaar, “The risk of cancer in users of statins,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2388–2394, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. S. J. Cho, J. S. Kim, J. M. Kim, J. Y. Lee, H. C. Jung, and I. S. Song, “Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts and attenuates colitis-associated colon cancer in mice,” International Journal of Cancer, vol. 123, no. 4, pp. 951–957, 2008. View at Publisher · View at Google Scholar
  19. C. Ukomadu and A. Dutta, “p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases,” The Journal of Biological Chemistry, vol. 278, no. 44, pp. 43586–43594, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Wächtershäuser, B. Akoglu, and J. Stein, “HMG-CoA reductase inhibitor mevastatin enhances the growth ihibitory effect of butyrate in the colorectal carcinoma cell line Caco-2,” Carcinogenesis, vol. 22, no. 7, pp. 1061–1067, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Agarwal, B. Halmos, A. S. Feoktistov et al., “Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells,” Carcinogenesis, vol. 23, no. 3, pp. 521–528, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. L. L. Kodach, R. J. Jacobs, P. W. Voorneveld et al., “Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell ‘stemness’ via the bone morphogenetic protein pathway,” Gut, vol. 60, no. 11, pp. 1544–1553, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Candeil, I. Gourdier, D. Peyron et al., “ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases,” International Journal of Cancer, vol. 109, no. 6, pp. 848–854, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Bergman, H. Salman, M. Djaldetti, and H. Bessler, “Statins as modulators of colon cancer cells induced cytokine secretion by human PBMC,” Vascular Pharmacology, vol. 54, no. 3–6, pp. 88–92, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Lee, I. Lee, B. Han et al., “Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations,” Journal of the National Cancer Institute, vol. 103, no. 8, pp. 674–688, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. H.-J. Park, D. Kong, L. Iruela-Arispe, U. Begley, D. Tang, and J. B. Galper, “3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA,” Circulation Research, vol. 91, no. 2, pp. 143–150, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. F. M. Vega and A. J. Ridley, “Rho GTPases in cancer cell biology,” FEBS Letters, vol. 582, no. 14, pp. 2093–2101, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. A. A. Al-Haidari, I. Syk, and H. Thorlacius, “HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation,” Biochemical and Biophysical Research Communications, vol. 446, no. 1, pp. 68–72, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. U. Sivaprasad, T. Abbas, and A. Dutta, “Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells,” Molecular Cancer Therapeutics, vol. 5, no. 9, pp. 2310–2316, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Cafforio, F. Dammacco, A. Gernone, and F. Silvestris, “Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells,” Carcinogenesis, vol. 26, no. 5, pp. 883–891, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Matusewicz, J. Meissner, M. Toporkiewicz, and A. F. Sikorski, “The effect of statins on cancer cells-review,” Tumor Biology, vol. 36, no. 7, pp. 4889–4904, 2015. View at Publisher · View at Google Scholar
  32. P. Rougier and E. Mitry, “Colorectal cancer chemotherapy: irinotecan,” Seminars in Oncology, vol. 27, no. 5, supplement 10, pp. 138–143, 2000. View at Google Scholar · View at Scopus
  33. T. Takahashi, Y. Fujiwara, M. Yamakido, O. Katoh, H. Watanabe, and P. I. Mackenzie, “The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro,” Japanese Journal of Cancer Research, vol. 88, no. 12, pp. 1211–1217, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. M. M. Gottesman, T. Fojo, and S. E. Bates, “Multidrug resistance in cancer: role of ATP-dependent transporters,” Nature Reviews Cancer, vol. 2, no. 1, pp. 48–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Litman, T. E. Druley, W. D. Stein, and S. E. Bates, “From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance,” Cellular and Molecular Life Sciences, vol. 58, no. 7, pp. 931–959, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Petitprez, V. Poindessous, D. Ouaret et al., “Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status,” International Journal of Oncology, vol. 42, no. 5, pp. 1644–1653, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Glodkowska-Mrowka, P. Mrowka, G. W. Basak et al., “Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib,” Experimental Hematology, vol. 42, no. 6, pp. 439–447, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. Á. Telbisz, M. Müller, C. Özvegy-Laczka et al., “Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter,” Biochimica et Biophysica Acta (BBA)—Biomembranes, vol. 1768, no. 11, pp. 2698–2713, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. P. D. W. Eckford and F. J. Sharom, “Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport,” Biochemistry, vol. 47, no. 51, pp. 13686–13698, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Rudolf, V. Kralova, K. Rudolf, and S. John, “The role of p38 in irinotecan-induced DNA damage and apoptosis of colon cancer cells,” Mutation Research, vol. 741-742, pp. 27–34, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. L.-U. Ling, H. Lin, K.-B. Tan, and G. N. C. Chiu, “The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells,” International Journal of Oncology, vol. 35, no. 6, pp. 1463–1471, 2009. View at Publisher · View at Google Scholar · View at Scopus